Aura Biosciences raises $99M in public offering; Q3 net loss $18.5M

Aura Biosciences, Inc.

2023-Q3 EPS reported -$1.43

Closed underwritten public offering of 11M shares at $9.00/share, gross proceeds $99.0M; net proceeds ~$92.6M.
Cash and securities $149.1M as of Sept 30, 2023; combined with offering proceeds, cash runway into H2 2026.
Q3 2023 net loss $18.5M vs $15.9M YoY; R&D expenses $15.4M (up from $11.3M) driven by Phase 2/3 trial costs.
Positive Phase 2 data for bel-sar in choroidal melanoma: 80% tumor control, 90% visual acuity preservation at 12 months.
FDA agreed under SPA for Phase 3 CoMpass trial design; first patient dosing expected Q4 2023.

item 1.01 item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Aura Biosciences, Inc. reported financial results for the third quarter ended September 30, 2023.

Period: the third quarter ended September 30, 2023
Result: reported results

Exact text from the filing

On November 9, 2023, the Company issued a press release announcing its financial results for the quarter ended September 30, 2023.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Aura Biosciences, Inc. entered into Underwriting Agreement with Leerink Partners LLC, Cowen and Company, LLC and Evercore Group L.L.C., as representatives of the several underwriters named therein valued at approximately $92.6 million (effective 2023-11-06).

Action: entry
Agreement: underwriting
Counterparty: Leerink Partners LLC, Cowen and Company, LLC and Evercore Group L.L.C., as representatives of the several underwriters named therein
Value: approximately $92.6 million
Effective: 2023-11-06

Exact text from the filing

On November 6, 2023, Aura Biosciences, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC, Cowen and Company, LLC and Evercore Group L.L.C., as representatives of the several underwriters named therein (the “Underwriters”), pursuant to which the Company agreed to issue and sell 11,000,000 shares of the Company’s common stock, par value $0.00001 per share (the “Common Stock”), to the Underwriters at a public offering price of $9.00 per share (the “Offering”).

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

Aura Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-062074

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.